Cited by 254Antifungal resistance and susceptibilityFungal Infections and StudiesHIV/AIDS oral health manifestations

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Open access

Arathoon, Eduardo G., Gotuzzo, Eduardo, Noriega, L. Miguel, Berman, Rayanne S., DiNubile, Mark J., Sable, Carole A.·2002·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.46.2.451-457.2002PMC PMC127070

Open this paper in CoChat — free account

Abstract

Caspofungin is an antifungal agent of the novel echinocandin class. We investigated its efficacy, safety, and tolerability as therapy for oropharyngeal and/or esophageal candidiasis in a phase II dose-ranging study. Patients were randomized in a double-blind manner to receive either caspofungin acetate (35, 50, or 70 mg) or amphotericin B (0.5 mg/kg of body weight) intravenously once daily for 7 to 14 days. A favorable response required both complete resolution of symptoms and quantifiable improvement of mucosal lesions 3 to 4 days after discontinuation of study drug. Efficacy was assessed using a modified intent-to-treat analysis. No hypothesis testing of efficacy was planned or performed. Of 140 enrolled patients, 63% had esophageal involvement and 98% were infected with the human immunodeficiency virus (HIV) (median CD4 count, 30/mm(3)). A modestly higher proportion of patients in each of the caspofungin groups (74 to 91%) achieved favorable responses compared to amphotericin B recipients (63%), but there was considerable overlap in the 95% confidence intervals surrounding these point estimates. Similar trends were found in the subgroups with esophageal involvement, a history of fluconazole failure, and CD4 counts of < or =50/mm(3). A smaller proportion of patients receiving any dose of caspofungin experienced drug-related adverse events compared to patients given standard doses of conventional amphotericin B (P < 0.01). Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study.

Integrity signals

Registry

Crossref · 10.1128/aac.46.2.451-457.2002

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Epidemiology of Human Immunodeficiency Virus–Associated Opportunistic Infections in the United States in the Era of Highly Active Antiretroviral Therapy
Kaplan, J. E., Hanson, D. L., Dworkin, M. S., Frederick, T., Bertolli, J., Lindegren, M. L., Holmberg, S. D., & Jones, J. L. (2000) · Clinical Infectious Diseases · doi:10.1086/313843 · Cited by 703
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322
International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A. K., Coffman, S. L., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
Ruhnke, M., Eigler, A., Tennagen, I., Geiseler, B., Engelmann, E., & Trautmann, M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.9.2092-2098.1994 · Cited by 250
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241
Esophageal infections: Risk factors, presentation, diagnosis, and treatment
Baehr, P. H., & McDonald, G. B. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90613-0 · Cited by 214
Current and future antifungal therapy: new targets for antifungal agents
Andriole, V. T. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.151 · Cited by 191

Flagged first, then by citations

Show all 46 references

Sorted by citations

Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Self-citation
Echinocandin antifungal drugs
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 907
Self-citation
Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy
Maertens, J., RAAD, I. I., Petrikkos, G. L., Boogaerts, M., Selleslag, D., Petersen, F. B., Sable, C. A., Kartsonis, N. A., Ngai, A. L., Taylor, A., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/423381 · Cited by 651
Self-citation
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
Pfaller, M. A., Diekema, D. J., Andes, D. R., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M. R., & Perlin, D. S. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.004 · Cited by 340
ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Caspofungin
Saravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 295
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
Villanueva, A., Gotuzzo, E., Arathoon, E., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 290
Self-citation
Oral mucosal fungal infections
Samaranayake, L. P., Leung, W. K., & Jin, L. (2008) · Periodontology 2000 · doi:10.1111/j.1600-0757.2008.00291.x · Cited by 279
Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility
Pfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
Multiechinocandin- and Multiazole-ResistantCandida parapsilosisIsolates Serially Obtained during Therapy for Prosthetic Valve Endocarditis
Moudgal, V. V., Little, T., Boikov, D. A., & Vázquez, J. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.767-769.2005 · Cited by 241
Untitled work
(2003) · PubMed · Cited by 240
Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents
Walsh, T. J., Adamson, P. C., Seibel, N. L., Flynn, P. M., Neely, M. N., Schwartz, C. L., Shad, A. T., Kaplan, S. L., Roden, M. M., Stone, J. A., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4536-4545.2005 · Cited by 238
Self-citation
Caspofungin: the first representative of a new antifungal class
Letscher‐Bru, V. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg117 · Cited by 235
Bench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
The Echinocandins
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Caspofungin Therapy of Neonates With Invasive Candidiasis
ODIO, C. M., Araya, R., Pinto, L. E., Castro, C. E. F., Vasquez, S., Alfaro, B., Saenz, A. H., Herrera, M. L., & Walsh, T. J. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000145408.51526.0a · Cited by 196
Nephrotoxicity of Antimicrobials and Antibiotics
Alvarez, M. C. M. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.001 · Cited by 199
Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin
Vázquez, J. A., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/505204 · Cited by 197
Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review
Bochud, P., Bonten, M. J. M., Marchetti, O., & Calandra, T. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000143118.41100.14 · Cited by 197
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 195
Clinical hepatotoxicity associated with antifungal agents
Kyriakidis, I., Tragiannidis, A., Munchen, S., & Groll, A. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1270264 · Cited by 191
Comparison of echinocandin antifungals
Eschenauer, G. A., DePestel, D. D., & Carver, P. L. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.71 · Cited by 184
A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS
Vázquez, J. A., Skiest, D. J., Nieto, L., Northland, R., Sanne, I., Gogate, J. P., Greaves, W. L., & ISAACS, R. E. (2006) · Clinical Infectious Diseases · doi:10.1086/501457 · Cited by 171
Reviews Of Anti‐infective Agents: New Agents for the Treatment of Fungal Infections: Clinical Efficacy and Gaps in Coverage
Spanakis, E. K., Aperis, G., & Mylonakis, E. E. (2006) · Clinical Infectious Diseases · doi:10.1086/507891 · Cited by 169
Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects with HIV Infection
Skiest, D. J., Vazquez, J. A., Anstead, G. M., Graybill, J. R., Reynes, J., Ward, D., Hare, R., Boparai, N., & Isaacs, R. (2007) · Clinical Infectious Diseases · doi:10.1086/511039 · Cited by 162
Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity
Louie, A., Deziel, M. R., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 164
Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis
Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases
Nami, S., Aghebati‐Maleki, A., Morovati, H., & Maleki, L. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.009 · Cited by 169
Clinical pharmacology of antifungal compounds
Groll, A. H., Gea‐Banacloche, J., Glasmacher, A., Just‐Nübling, G., Maschmeyer, G., & Walsh, T. J. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00068-5 · Cited by 157
Discovery and development of first in class antifungal caspofungin (CANCIDAS®)—A case study
Balkovec, J. M., Hughes, D. L., Masurekar, P. S., Sable, C. A., Schwartz, R. E., & Singh, S. B. (2013) · Natural Product Reports · doi:10.1039/c3np70070d · Cited by 156
Self-citation
Caspofungin: the first in a new class of antifungal agents
Kartsonis, N. A., NIELSEN, J. B. K., & Douglas, C. M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00064-5 · Cited by 146
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma
Stone, J. A., Xu, X., Winchell, G. A., Deutsch, P., Pearson, P. G., Migoya, E. M., Mistry, G. C., Xi, L., Miller, A. R., Sandhu, P., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.815-823.2004 · Cited by 138
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome
Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 138
Self-citation
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 140
Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age
Sáez‐Llorens, X., Macías-Parra, M., Maiya, P. P., Piñeros, J. G., Jafri, H. S., Chatterjee, A., Ruiz, G., Raghavan, J., Bradshaw, S. K., Kartsonis, N. A., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00868-08 · Cited by 136
Recent advances in antifungal chemotherapy
Petrikkos, G. L., & Skiada, A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.03.009 · Cited by 127
The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications
Wagner, C. C., Graninger, W., Presterl, E., & Joukhadar, C. (2006) · Pharmacology · doi:10.1159/000096348 · Cited by 123
Caspofungin
McCormack, P. L., & Perry, C. M. (2005) · Drugs · doi:10.2165/00003495-200565140-00009 · Cited by 122
Candida tropicalisin human disease
Chai, L. Y. A., Denning, D. W., & Warn, P. A. (2010) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2010.489506 · Cited by 130
Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit
Nguyen, T. H., Hoppe‐Tichy, T., Geiss, H. K., Rastall, A. C., Swoboda, S., Schmidt, J., & Weigand, M. A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm125 · Cited by 118
HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN
Sandhu, P., Lee, W., Xu, X., Leake, B. F., Yamazaki, M., Stone, J. A., Lin, J. H., Pearson, P. G., & Kim, R. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003244 · Cited by 109
ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
Lortholary, O., Πετρίκκος, Γ., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12042 · Cited by 108
New antifungal agents
Gupta, A. K., & Tomas, E. T. (2003) · Dermatologic Clinics · doi:10.1016/s0733-8635(03)00024-x · Cited by 108
A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients
Zaoutis, T. E., Jafri, H. S., Huang, L., Locatelli, F., Barzilai, A., Ebell, W., Steinbach, W. J., Bradley, J. S., Lieberman, J. M., Hsiao, C., et al. (2009) · PEDIATRICS · doi:10.1542/peds.2008-1158 · Cited by 108
Recent Approaches to Antifungal Therapy for Invasive Mycoses
Mathew, B. P., & Nath, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800353 · Cited by 105
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children
Pienaar, E. D., Young, T., & Holmes, H. K. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003940.pub3 · Cited by 104
Potential for Interactions between Caspofungin and Nelfinavir or Rifampin
Stone, J. A., Migoya, E. M., Hickey, L., Winchell, G. A., Deutsch, P., Ghosh, K., Freeman, A., Bi, S., Desai, R., Dilzer, S. C., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4306-4314.2004 · Cited by 99
Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections
Cornely, O. A. (2008) · Infection · doi:10.1007/s15010-008-7357-z · Cited by 98
Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis
Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05134-11 · Cited by 93
Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review
Blyth, C. C., Palasanthiran, P., & O'Brien, T. A. (2007) · PEDIATRICS · doi:10.1542/peds.2006-2931 · Cited by 93
Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93
Fluconazole for the treatment of candidiasis: 15 years experience
Cha, R., & Sobel, J. D. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.3.357 · Cited by 90
Treatment options of invasive fungal infections in adults
Marchetti, O., Eggimann, P., Pittet, D., Glauser, M., & Calandra, T. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11392 · Cited by 90
Gastrointestinal infections in immunocompromised hosts
Thom, K. A., & Forrest, G. N. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mog.0000196149.29077.0d · Cited by 88
Echinocandins in the management of invasive fungal infections, part 1
Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p1 · Cited by 86
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
Current Options in Antifungal Pharmacotherapy
Mohr, J., Johnson, M. D., Cooper, T., Lewis, J. S., & Ostrosky-Zeichner, L. L. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.614 · Cited by 89
Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole
Ullmann, A. J. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001884 · Cited by 84
Management of Invasive Candidiasis in Critically Ill Patients
Blot, S. I., & Vandewoude, K. (2004) · Drugs · doi:10.2165/00003495-200464190-00002 · Cited by 80
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
Vazquez, J. (2010) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s6660 · Cited by 87
Efficacy of Caspofungin in the Treatment of Esophageal Candidiasis Resistant to Fluconazole
Kartsonis, N., DiNubile, M. J., Bartizal, K., Hicks, P. S., Ryan, D., & Sable, C. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200210010-00009 · Cited by 77
Self-citation
Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers
Neely, M. N., Jafri, H. S., Seibel, N. L., Knapp, K. M., Adamson, P. C., Bradshaw, S. K., Strohmaier, K. M., Sun, P. G., Bi, S., Dockendorf, M. F., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01027-08 · Cited by 76
Caspofungin
Keating, G. M., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363200-00008 · Cited by 75
Antifungal chemotherapy: advances and perspectives
Groll, A. H., & Walsh, T. J. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09729 · Cited by 76
Overview of treatment options for invasive fungal infections
Pound, M. W., Townsend, M. L., DiMondi, V. P., Wilson, D. T., & Drew, R. H. (2011) · Medical Mycology · doi:10.3109/13693786.2011.560197 · Cited by 69
Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies
Candoni, A., Mestroni, R., Damiani, D., Tiribelli, M., Michelutti, A., Silvestri, F., Castelli, M., Viale, P., & Fanin, R. (2005) · European Journal of Haematology · doi:10.1111/j.1600-0609.2005.00500.x · Cited by 67
Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection
Vázquez, J. A., Skiest, D. J., Tissot‐Dupont, H., Lennox, J. L., Boparai, N., & Isaacs, R. (2007) · HIV Clinical Trials · doi:10.1310/hct0802-86 · Cited by 66
Oral Candidosis in HIV-Infected Patients
Egusa, H., Soysa, N. S., Ellepola, A. N. B., Yatani, H., & Samaranayake, L. P. (2008) · Current HIV Research · doi:10.2174/157016208786501445 · Cited by 69
Antifungals to treatCandida albicans
Moudgal, V. V., & Sobel, J. D. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.493875 · Cited by 69
Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations
Mistry, G. C., Migoya, E. M., Deutsch, P., Winchell, G. A., Hesney, M., Li, S., Bi, S., Dilzer, S. C., Lasseter, K. C., & Stone, J. A. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303764 · Cited by 64
Micafungin: A New Echinocandin Antifungal
Joseph, J., Jain, R., & Danziger, L. H. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.1.53 · Cited by 64
Retrospective study of the safety of caspofungin in immunocompromised pediatric patients
Franklin, J. A., McCormick, J., & Flynn, P. M. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000078164.80233.14 · Cited by 65
Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study
Kartsonis, N. A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh179 · Cited by 61
Topical Caspofungin for Treatment of Keratitis Caused by Candida albicans in a Rabbit Model
Goldblum, D., Frueh, B. E., Sarra, G., Κatsoulis, Κ., & Zimmerli, S. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1359-1363.2005 · Cited by 59
Treatment of Candida Infections with Amphotericin B Lipid Complex
Ito, J. I., & Hooshmand-Rad, R. (2005) · Clinical Infectious Diseases · doi:10.1086/429330 · Cited by 60
Traditional and Emerging Antifungal Therapies
Arnold, T. M., Dotson, E. K., Sarosi, G. A., & Hage, C. A. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200906-048al · Cited by 57
Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis
Würthwein, G., Cornely, O. A., Trame, M. N., Vehreschild, J. J., Vehreschild, M. J. G. T., Farowski, F., Müller, C., Boos, J., Hempel, G., Hallek, M. J., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01912-12 · Cited by 54
Development of Candidemia on Caspofungin Therapy: a Case Report
Cheung, C. N., Guo, Y., Gialanella, P., & Feldmesser, M. (2006) · Infection · doi:10.1007/s15010-006-5613-7 · Cited by 53
The first echinocandin: caspofungin
Cornely, O. A., Schmitz, K., & Aisenbrey, S. (2002) · Mycoses · doi:10.1111/j.1439-0507.2002.tb04771.x · Cited by 53
Efficacy and mechanism of actions of natural antimicrobial drugs
Ye, L., Zhang, J., Xiao, W. L., & Liu, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107671 · Cited by 52
Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections
Slavin, M. A., Szer, J., Grigg, A., Roberts, A. W., Seymour, J. F., Sasadeusz, J., Thursky, K., Chen, S. C., Morrissey, C. O., Heath, C. H., et al. (2004) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2004.00541.x · Cited by 51
A comparative evaluation of properties and clinical efficacy of the echinocandins
Kim, R., Khachikian, D., & Reboli, A. C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1479 · Cited by 49
Disposition of Caspofungin, a Novel Antifungal Agent, in Mice, Rats, Rabbits, and Monkeys
Sandhu, P., Xu, X., Bondiskey, P. J., Balani, S. K., Morris, M. L., Tang, Y. S., Miller, A. R., & Pearson, P. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1272-1280.2004 · Cited by 49
Emerging echinocandins for treatment of invasive fungal infections
Turner, M., Drew, R. H., & Perfect, J. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.231 · Cited by 49
Ocular penetration of caspofungin in a rabbit uveitis model
Goldblum, D., Fausch, K., Frueh, B. E., Theurillat, R., Thormann, W., & Zimmerli, S. (2006) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-006-0460-x · Cited by 46
Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts
Metcalf, S. C., & Dockrell, D. H. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.06.012 · Cited by 47
Echinocandins: role in antifungal therapy, 2005
Zaas, A. K., & Alexander, B. D. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1657 · Cited by 45
An update on the use of antifungal agents.
Martínez, R. (2006) · PubMed · Cited by 42
Response and Relapse Rates of Candidal Esophagitis in HIV-Infected Patients Treated with Caspofungin
DiNubile, M. J., Lupinacci, R. J., Berman, R. S., & Sable, C. A. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760265579 · Cited by 42
Self-citation
Management of systemic fungal infections: alternatives to itraconazole
Herbrecht, R., Nivoix, Y., Fohrer, C., Natarajan‐Amé, S., & Letscher‐Bru, V. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki223 · Cited by 41

Authors: Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A.
Affiliations: Hospital General San Juan de Dios (GT)
Hospital Nacional Cayetano Heredia (PE)
Complejo Asistencial Sótero del Río (CL)
Merck Research Laboratories, West Point, Pennsylvania
Corresponding author: DiNubile, Mark J.
ORCID: Arathoon, Eduardo G.
Gotuzzo, Eduardo
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2002-02
Volume: 46
Issue: 2
Pages: 451-457
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.46.2.451-457.2002
PMC: PMC127070
OpenAlex: W2156228013
Cited by: 254
References: 46
Citations by year: 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 6 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 8 · 2014: 8 · 2013: 4 · 2012: 7
FWCI: 18.98
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Health Sciences › Dentistry › General Dentistry › HIV/AIDS oral health manifestations
Keywords: caspofungin, amphotericin B, oropharyngeal candidiasis, esophageal candidiasis, HIV infection, CD4 count, drug safety and tolerability, dose-ranging
MeSH terms: Caspofungin, Adolescent, Adult, Aged, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candidiasis, Double-Blind Method, Drug Tolerance, Esophageal Diseases, Female, Humans, Male, Middle Aged, Peptides, Peptides, Cyclic, Pharyngeal Diseases, Treatment Outcome, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks